


Growing pipeline across three therapeutic areas



Oncology
 Rare Disease
 Neuroscience

Information shown as of March 2026

IPSEN RAF: Rapidly Accelerated Fibrosarcoma; **1L**: First Line; **pLGG**: Pediatric Low-Grade Glioma; **BTN3A**: Butyrophilin-3A; **Unfit**: including high risk patients who are ineligible for intensive chemotherapy; **AML**: Acute Myeloid Leukemia; **RAFi**: RAF inhibitor of the MAPK pathway; **ADC**: Antibody-Drug Conjugate; **TCA**: T-Cell Activator; **PPAR**: Peroxisome Proliferator-Activated Receptor; **PBC**: Primary Biliary Cholangitis; **PSC**: Primary Sclerosing Cholangitis; **IBATi**: Ileal Bile Acid Transporter Inhibitor; **BA**: Biliary Atresia; **BoNTA**: Botulinum Toxin Serotype A; **C/E**: Chronic/Episodic; **GL**: Glabellar Lines; **Ax**: Aesthetics; **FHL**: Forehead Lines; **LCL**: Lateral Canthal Lines; **AUL**: Adult Upper Limb Spasticity; **Tx**: Therapeutics; ¹ Executed by Day One Biopharmaceuticals